Publication Reference

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer 2016; 114(5): 505-509.

Conference Presentation Reference

1. Tebbutt NC, Gebski VJ, Hall M, Wong N, Veillard AS, Wilcken N, Price TJ. Randomised, phase II study of weekly docetaxel, cisplatin and 5-fluorouracil or capecitabine given with or without panitumumab in advanced oesophago-gastric cancer: the AGITG ATTAX 3 trial. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne.
2. Tebbutt N, Price T, Sjoquist K, Veillard A, Hall M, Ferraro D, Wong N, Pavlakis M, Strickland A, Varma S, Cooray P, Young R, Underhill C, Shannon J, Ganju V, Gebski V, Group. AGT. Final results of AGITG ATTAX3 study: randomized phase II study of weekly docetaxel, cisplatin, and fluoropyrimidine with or without panitumumab in advanced esophagogastric cancer. American Society of Clinical Oncology Annual Meeting; 31 May–4 Jun 2013; Chicago. Journal of Clinical Oncology; 31 (suppl.): 4081.

Aim

The aim of ATTAX-3 is to evaluate whether the addition of the drug panitumumab can improve the results achieved using the standard chemotherapy regimen. This study will also be used to collect more information about the safety of panitumumab, when given in combination with standard anti−cancer treatment.

Summary

Most cases of oesophageal and gastric cancer are locally advanced or metastatic at presentation. Chemotherapy prolongs survival and improves the quality of life of patients, but standard chemotherapy for this disease is as yet undefined.

Principal Investigator

Dr Niall Tebbutt